SUMMIT THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.65 USD | -2.72% |
|
+5.92% | +78.16% |
| May. 07 | Citigroup Starts Summit Therapeutics With Buy Rating, $7 Price Target | MT |
| May. 01 | Transcript : Summit Therapeutics Inc., Q1 2024 Earnings Call, May 01, 2024 |
Presenter SpeechNatalie Collins (Analysts)Hi, everyone, and welcome to the 41st Annual JPMorga...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
Calendar
2024-06-14
- Annual General Meeting
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.716
GBP
Average target price
5.994
GBP
Spread / Average Target
+61.30%
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +78.16% | 3.26B | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- SMMT Stock
- News Summit Therapeutics Inc.
- Transcript : Summit Therapeutics Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-09-2023 03
